Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPIX |
---|---|---|
09:32 ET | 1449 | 6.75 |
09:38 ET | 2700 | 6.7674 |
09:41 ET | 600 | 6.64 |
09:43 ET | 250 | 6.5595 |
09:50 ET | 500 | 6.55 |
09:54 ET | 2700 | 6.65 |
09:57 ET | 100 | 6.615 |
10:24 ET | 700 | 6.56 |
10:42 ET | 1583 | 6.615 |
11:13 ET | 100 | 6.53 |
11:42 ET | 100 | 6.53 |
12:00 ET | 111 | 6.63 |
12:36 ET | 600 | 6.56 |
12:54 ET | 1897 | 6.6 |
01:26 ET | 2200 | 6.64 |
01:35 ET | 300 | 6.71 |
01:42 ET | 1000 | 6.64 |
01:48 ET | 500 | 6.645 |
02:02 ET | 200 | 6.64 |
02:08 ET | 100 | 6.645 |
02:11 ET | 100 | 6.645 |
02:18 ET | 100 | 6.65 |
02:24 ET | 1850 | 6.65 |
02:45 ET | 100 | 6.56 |
02:54 ET | 200 | 6.57 |
03:21 ET | 100 | 6.67 |
03:34 ET | 100 | 6.67 |
03:36 ET | 500 | 6.67 |
03:41 ET | 415 | 6.77 |
03:54 ET | 100 | 6.58 |
03:56 ET | 100 | 6.56 |
03:57 ET | 900 | 6.565 |
03:59 ET | 970 | 6.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ESSA Pharma Inc | 299.5M | -10.7x | --- |
Inozyme Pharma Inc | 298.1M | -3.5x | --- |
Atea Pharmaceuticals Inc | 309.1M | -1.9x | --- |
Q32 Bio Inc | 304.5M | -1.0x | --- |
Solid Biosciences Inc | 317.0M | -2.1x | --- |
Alto Neuroscience Inc | 321.5M | -6.3x | --- |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $299.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-0.63 |
Book Value | $3.30 |
P/E Ratio | -10.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.